TITLE:
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

CONDITION:
HIV Infections

INTERVENTION:
tipranavir

SUMMARY:

      This is an open-label, randomized, parallel group pharmacokinetics trial of
      tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV),
      amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple
      antiretroviral (ARV) experienced HIV-1 patients.

      The primary objective is to determine the safety and pharmacokinetics of:

      TPV/RTV given with an optimized background regimen (OBR) and TPV/RTV given in combination
      with saquinavir, amprenavir, or Kaletra and an optimized background regimen (OBR).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:
NONE
